Editorials

BCG vaccine in superficial bladder cancer

BMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6932.801 (Published 26 March 1994) Cite this as: BMJ 1994;308:801
  1. Neeraj Sharma,
  2. Stephen Prescott

    The most effective form of immunotherapy for solid tumours is still poorly understood

    The main risks from superficial bladder cancer are that it may recur or that it may progress to invasive disease with a high mortality. Immunotherapy with live BCG vaccine was shown to be an effective treatment as long ago as 1976,1 and the vaccine is still the only intravesical agent to have been shown to reduce both of these risks.2

    Factors that increase the risk of progression are high tumour grade, invasion of the lamina propria, and the presence of carcinoma in situ.3 The main indications for the use of BCG vaccine in Britain are treatment of carcinoma in situ of the bladder; treatment of residual superficial papillary tumour; and prophylaxis against recurrence of superficial tumours and against progression after resection of a tumour.

    No one questions the use of BCG vaccine for diffuse carcinoma in situ. This condition is difficult to eradicate by resection--indeed, if treated by surgery alone it progresses to invasion of the …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe